Navigation Links
NIH awards Phylonix phase II SBIR to develop zebrafish models for eye diseases
Date:10/2/2007

Cambridge, MA October 2, 2007 Phylonix Pharmaceuticals, Inc. today announced that it has been awarded a $1,092,031 Phase II Small Business Innovation Grant (SBIR) from the National Eye Institute of the National Institutes of Health (NIH) to develop zebrafish eye disease models for drug screening. The grant for New Models for Eye Diseases will support the Phylonix program over a period of three years.

The eye is a highly conserved organ and the basic structure between human and zebrafish eyes is indistinguishable. In addition, numerous eye diseases have been modeled in zebrafish including choroidal neovascularization, similar to age-related macular degeneration (AMD) in humans; ocular scarring that occurs after surgery for glaucoma; retinopathy induced by diabetes and edema; and ocular ischemia caused by several pathologies.

The funding for this program will be used to further develop our novel, patent pending methods for modeling eye diseases and to identify potential drug candidates, commented Patricia McGrath, Phylonix President and Chief Executive Officer. Our preliminary data show good correlation between results in zebrafish and results in mammals and we are very pleased to receive this Phase II SBIR award from the National Eye Institute.

Phylonix is modeling a number of eye diseases in zebrafish including diabetic retinopathy and AMD, the two leading causes of blindness in adults in the industrialized world. Both conditions involve vascular abnormalities, proliferation and leakage of new blood vessels. Other eye diseases resulting in blindness that Phylonix is modeling in zebrafish include retinopathy of prematurity, a major cause of newborn blindness in premature infants maintained by oxygen supplementation during the postnatal period. This disease involves intense neovascularization of the retina and leads to retinal detachment. Another cause of blindness is corneal neovascularization, which often results from injury and infection in the cornea.

Current mammalian models for ocular neovascularization require lengthy, tedious surgical manipulation and do not always result in improved vision; an alternative rapid, less invasive animal model for studying the process of ocular neovascularization and assessing drug effects will facilitate identification of new therapeutics. As the population ages, the incidence of eye diseases is rapidly increasing and convenient methods for assessing single and combination therapies in whole animals are urgently needed.

Advantages of using zebrafish for compound screening

Laboratory animals are critical for defining the mechanisms of drug activity and for testing therapeutic regimens, however, only a few useful models have been developed. Zebrafish has several important advantages for drug screening: they are small, inexpensive to maintain, and easily bred in large numbers. Zebrafish eggs are externally fertilized and a single mating produces 100-200 eggs. Single embryos can be maintained in fluid volumes as small as 100 microliters for the first six days of development and cultured in microtiter wells. Chemicals can then be added directly to the fish water, permeating the intact embryos. Standard microtiter plate readers can be used for quantitation, making this format particularly attractive for high-throughput drug screening.

Phylonix is developing a family of zebrafish assays with compelling advantages: 1) short assay time, 2) single dosing, 3) small amount of drug required for each test, 4) statistically significant numbers of animals can be assayed for each condition, 5) embryos maintenance during drug delivery is easy, and 6) low cost the estimated cost of each zebrafish assay is less than $100. Chemicals, small molecules, proteins, and nucleic acids such as knock-down reagents can be assessed using the Phylonix zebrafish assays.


'/>"/>

Contact: Edward O'Lear
ed.olear@phylonix.com
617-441-6700
Phylonix
Source:Eurekalert

Related medicine news :

1. Aussie Nobel Prize Winners Receive Their Awards
2. Prestigious Gairdner Awards for medical research in 2006 Goes To Two Yale biologists
3. The President Gives Away National Disability Awards
4. Majority of Padma Awards Go to Doctors from Delhi
5. US, Indian Doctors Bag Thai Medical Awards
6. WHO Awards Prequalification Status to the First UAE Approved Vaccine
7. Bio-Rad Gets Life Science Industry Awards – 200
8. Michael J. Fox Foundation Awards $710,000 to Understanding of Parkinsons Disease Subtypes
9. Ontario Court Awards Compensation To Paralyzed Worker
10. Talwalkars Awards a Record $1 Million Order to Nautilus
11. NIH Awards Emory $3.6 Million for Schizophrenia Gene Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... videos a whole new perspective by using the title layers in ProSlice Levels ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
Breaking Medicine Technology: